cellulitis_erysipelas
CELLULITIS/ERYSIPELAS
Cellulitis is a spreading bacterial skin infection that infects deeply involving the subcutaneous tissues.
It typically occurs in areas where the skin integrity has been compromised.
It may also result from blood-borne spread of infection to the skin and subcutaneous tissues.
It is commonly caused by beta-hemolytic streptococci and Staphylococcus aureus.
Erysipelas is a type of cellulitis with margins that are sharply demarcated, involves the epidermis and superficial lymphatics.
Onset of symptoms is acute whereas cellulitis has an indolent course.
It is more commonly caused by beta-hemolytic streptococci.

Patient Education

  • Advise on good personal hygiene and wound care
    • Cover draining wounds with clean bandage
    • Regularly bathe and wash hands after coming in contact with a wound
    • Avoid sharing or reusing items that came in contact with infected skin
    • Inspect interdigital toe spaces regularly especially if with lower extremity cellulitis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
07 Jun 2018
Recurrent acute uncomplicated urinary tract infection (UTI) negatively affects quality of life (QOL), including physical and mental health status, in premenopausal women, according to a study. QOL may even be lower in UTI-infected women with comorbid chronic constipation or who consume caffeine.
Pank Jit Sin, 12 Jun 2018
The common antimicrobial agent, triclosan, has been implicated in colonic inflammation and the disease development of colitis and colitis-associated colon cancer, reveals a study appearing in Science Translational Medicine. [doi:10.1126/scitranslmed.aan4116] 
Roshini Claire Anthony, 30 May 2018

The use of procalcitonin assays had little impact on antibiotic exposure in patients who presented to emergency departments (ED) with suspected lower respiratory tract infections, according to findings of the ProACT* trial presented at the recent sessions of the American Thoracic Society (ATS 2018).